Novel C-aryl-d-glucofuranosides were synthesized and evaluated for their capacity to inhibit human sodium-dependent glucose co-transporter 2 (hSGLT2) and hSGLT1. Compound 21q demonstrated the best in vitro inhibitory activity against SGLT2 in this series (EC50 = 0.62 μM).
Date:
2013-11
Relation:
Bioorganic and Medicinal Chemistry. 2013 Nov;21(21):6282-6291.